Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation
Atrial natriuretic peptide (ANP) is a circulating hormone released from the atria in response to wall stretch and volume overload in the setting of heart failure. When atrial fibrillation (AF) becomes long-standing persistent, ANP secretion in response to volume overload is impaired due to degenerat...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2024-10, Vol.16 (10), p.e71844 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 10 |
| container_start_page | e71844 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 16 |
| creator | Kurisu, Satoshi Fujiwara, Hitoshi |
| description | Atrial natriuretic peptide (ANP) is a circulating hormone released from the atria in response to wall stretch and volume overload in the setting of heart failure. When atrial fibrillation (AF) becomes long-standing persistent, ANP secretion in response to volume overload is impaired due to degenerative changes of the atria. Here, we report a case of heart failure with preserved ejection fraction and impaired ANP secretion due to long-standing AF. N-terminal pro-brain natriuretic peptide (NT-proBNP) level was elevated (269 pg/mL), whereas the increase in ANP level was marginal (46.1 pg/mL), suggesting impaired ANP secretion due to long-standing AF. Valsartan (80 mg/day) was replaced with sacubitril/valsartan (100 mg/day) without changing other medications. Administration of sacubitril/valsartan was effective in improving the patient's symptoms, such as dyspnea and edema, and reducing NT-proBNP level by increasing endogenous ANP level from 46.1 pg/mL to 117 pg/mL in the first four weeks. This case highlights the possibility of impaired ANP secretion in response to volume overload as a predictor of the diuretic effect of sacubitril/valsartan in heart failure. This may lead to individualized treatment for each patient with heart failure based on natriuretic peptide profiles. |
| doi_str_mv | 10.7759/cureus.71844 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11571103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3134455261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2154-b690db3a7a2210d6b6c0812df192deca69e8fbd0619fd1159ac98897f42804f03</originalsourceid><addsrcrecordid>eNpdksluFDEQhi0EIlHIjTOyxIUDndju1ScUhUwSaQSRhuVoVXuZOOqxJ16Q8ki8ZdzMEAVOZVf9_uovuRB6S8lJ37f8VOagczzp6dA0L9Aho91QDeXy8tn5AB3HeEcIoaRnpCev0UHN25Z3hByi3xfGWAnyAXuDVyDzaFOw0-kPmCKEBA5bhwHfQLLaJfzTplt8pUsFL8BOpTsGp_D1Zgs2aIVXWgadrHcz7qyQYMJfoMQ8pyW-0dtklcafs8bJ46V362pVuijr1qUYoo1p7rN_urBjMTPBTHyDXpliSh_v4xH6vrj4dn5VLb9eXp-fLSvJaNtUY8eJGmvogTFKVDd2kgyUKUM5U1pCx_VgRkU6yo2itOUg-TDw3jRsII0h9RH6tONu87jRShY7ASaxDXYD4UF4sOLfirO3Yu1_iQLrKSV1IXzYE4K_zzomsbFR6jKH0z5HUdOaFG8NbYv0_X_SO5-DK_PNqqZpW9bRovq4U8ngYwzaPLmhRMx7IHZ7IP7sQZG_ez7Bk_jvr9ePmvCx-A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3134455261</pqid></control><display><type>article</type><title>Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Kurisu, Satoshi ; Fujiwara, Hitoshi</creator><creatorcontrib>Kurisu, Satoshi ; Fujiwara, Hitoshi</creatorcontrib><description>Atrial natriuretic peptide (ANP) is a circulating hormone released from the atria in response to wall stretch and volume overload in the setting of heart failure. When atrial fibrillation (AF) becomes long-standing persistent, ANP secretion in response to volume overload is impaired due to degenerative changes of the atria. Here, we report a case of heart failure with preserved ejection fraction and impaired ANP secretion due to long-standing AF. N-terminal pro-brain natriuretic peptide (NT-proBNP) level was elevated (269 pg/mL), whereas the increase in ANP level was marginal (46.1 pg/mL), suggesting impaired ANP secretion due to long-standing AF. Valsartan (80 mg/day) was replaced with sacubitril/valsartan (100 mg/day) without changing other medications. Administration of sacubitril/valsartan was effective in improving the patient's symptoms, such as dyspnea and edema, and reducing NT-proBNP level by increasing endogenous ANP level from 46.1 pg/mL to 117 pg/mL in the first four weeks. This case highlights the possibility of impaired ANP secretion in response to volume overload as a predictor of the diuretic effect of sacubitril/valsartan in heart failure. This may lead to individualized treatment for each patient with heart failure based on natriuretic peptide profiles.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.71844</identifier><identifier>PMID: 39559600</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Blood ; Cardiac arrhythmia ; Cardiology ; Creatinine ; Doppler effect ; Dyspnea ; Edema ; Ejection fraction ; Electrocardiography ; Heart failure ; Hemoglobin ; Hospitalization ; Hospitals ; Internal Medicine ; Kinases ; Peptides ; Pharmacology ; Thyroid gland ; Ultrasonic imaging</subject><ispartof>Curēus (Palo Alto, CA), 2024-10, Vol.16 (10), p.e71844</ispartof><rights>Copyright © 2024, Kurisu et al.</rights><rights>Copyright © 2024, Kurisu et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2024, Kurisu et al. 2024 Kurisu et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2154-b690db3a7a2210d6b6c0812df192deca69e8fbd0619fd1159ac98897f42804f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571103/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571103/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39559600$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kurisu, Satoshi</creatorcontrib><creatorcontrib>Fujiwara, Hitoshi</creatorcontrib><title>Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Atrial natriuretic peptide (ANP) is a circulating hormone released from the atria in response to wall stretch and volume overload in the setting of heart failure. When atrial fibrillation (AF) becomes long-standing persistent, ANP secretion in response to volume overload is impaired due to degenerative changes of the atria. Here, we report a case of heart failure with preserved ejection fraction and impaired ANP secretion due to long-standing AF. N-terminal pro-brain natriuretic peptide (NT-proBNP) level was elevated (269 pg/mL), whereas the increase in ANP level was marginal (46.1 pg/mL), suggesting impaired ANP secretion due to long-standing AF. Valsartan (80 mg/day) was replaced with sacubitril/valsartan (100 mg/day) without changing other medications. Administration of sacubitril/valsartan was effective in improving the patient's symptoms, such as dyspnea and edema, and reducing NT-proBNP level by increasing endogenous ANP level from 46.1 pg/mL to 117 pg/mL in the first four weeks. This case highlights the possibility of impaired ANP secretion in response to volume overload as a predictor of the diuretic effect of sacubitril/valsartan in heart failure. This may lead to individualized treatment for each patient with heart failure based on natriuretic peptide profiles.</description><subject>Blood</subject><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Creatinine</subject><subject>Doppler effect</subject><subject>Dyspnea</subject><subject>Edema</subject><subject>Ejection fraction</subject><subject>Electrocardiography</subject><subject>Heart failure</subject><subject>Hemoglobin</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Peptides</subject><subject>Pharmacology</subject><subject>Thyroid gland</subject><subject>Ultrasonic imaging</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdksluFDEQhi0EIlHIjTOyxIUDndju1ScUhUwSaQSRhuVoVXuZOOqxJ16Q8ki8ZdzMEAVOZVf9_uovuRB6S8lJ37f8VOagczzp6dA0L9Aho91QDeXy8tn5AB3HeEcIoaRnpCev0UHN25Z3hByi3xfGWAnyAXuDVyDzaFOw0-kPmCKEBA5bhwHfQLLaJfzTplt8pUsFL8BOpTsGp_D1Zgs2aIVXWgadrHcz7qyQYMJfoMQ8pyW-0dtklcafs8bJ46V362pVuijr1qUYoo1p7rN_urBjMTPBTHyDXpliSh_v4xH6vrj4dn5VLb9eXp-fLSvJaNtUY8eJGmvogTFKVDd2kgyUKUM5U1pCx_VgRkU6yo2itOUg-TDw3jRsII0h9RH6tONu87jRShY7ASaxDXYD4UF4sOLfirO3Yu1_iQLrKSV1IXzYE4K_zzomsbFR6jKH0z5HUdOaFG8NbYv0_X_SO5-DK_PNqqZpW9bRovq4U8ngYwzaPLmhRMx7IHZ7IP7sQZG_ez7Bk_jvr9ePmvCx-A</recordid><startdate>20241019</startdate><enddate>20241019</enddate><creator>Kurisu, Satoshi</creator><creator>Fujiwara, Hitoshi</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20241019</creationdate><title>Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation</title><author>Kurisu, Satoshi ; Fujiwara, Hitoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2154-b690db3a7a2210d6b6c0812df192deca69e8fbd0619fd1159ac98897f42804f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Blood</topic><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Creatinine</topic><topic>Doppler effect</topic><topic>Dyspnea</topic><topic>Edema</topic><topic>Ejection fraction</topic><topic>Electrocardiography</topic><topic>Heart failure</topic><topic>Hemoglobin</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Peptides</topic><topic>Pharmacology</topic><topic>Thyroid gland</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kurisu, Satoshi</creatorcontrib><creatorcontrib>Fujiwara, Hitoshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kurisu, Satoshi</au><au>Fujiwara, Hitoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2024-10-19</date><risdate>2024</risdate><volume>16</volume><issue>10</issue><spage>e71844</spage><pages>e71844-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Atrial natriuretic peptide (ANP) is a circulating hormone released from the atria in response to wall stretch and volume overload in the setting of heart failure. When atrial fibrillation (AF) becomes long-standing persistent, ANP secretion in response to volume overload is impaired due to degenerative changes of the atria. Here, we report a case of heart failure with preserved ejection fraction and impaired ANP secretion due to long-standing AF. N-terminal pro-brain natriuretic peptide (NT-proBNP) level was elevated (269 pg/mL), whereas the increase in ANP level was marginal (46.1 pg/mL), suggesting impaired ANP secretion due to long-standing AF. Valsartan (80 mg/day) was replaced with sacubitril/valsartan (100 mg/day) without changing other medications. Administration of sacubitril/valsartan was effective in improving the patient's symptoms, such as dyspnea and edema, and reducing NT-proBNP level by increasing endogenous ANP level from 46.1 pg/mL to 117 pg/mL in the first four weeks. This case highlights the possibility of impaired ANP secretion in response to volume overload as a predictor of the diuretic effect of sacubitril/valsartan in heart failure. This may lead to individualized treatment for each patient with heart failure based on natriuretic peptide profiles.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>39559600</pmid><doi>10.7759/cureus.71844</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2024-10, Vol.16 (10), p.e71844 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11571103 |
| source | PubMed Central Open Access; PubMed Central |
| subjects | Blood Cardiac arrhythmia Cardiology Creatinine Doppler effect Dyspnea Edema Ejection fraction Electrocardiography Heart failure Hemoglobin Hospitalization Hospitals Internal Medicine Kinases Peptides Pharmacology Thyroid gland Ultrasonic imaging |
| title | Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A58%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Sacubitril/Valsartan%20in%20a%20Patient%20With%20Heart%20Failure%20and%20Impaired%20Secretion%20of%20Atrial%20Natriuretic%20Peptide%20Due%20to%20Long-Standing%20Persistent%20Atrial%20Fibrillation&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Kurisu,%20Satoshi&rft.date=2024-10-19&rft.volume=16&rft.issue=10&rft.spage=e71844&rft.pages=e71844-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.71844&rft_dat=%3Cproquest_pubme%3E3134455261%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3134455261&rft_id=info:pmid/39559600&rfr_iscdi=true |